{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/5b0fd1107b67904376d520f7/5fad231fbc034454b53fdfab?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"The new vaccine chapter for value stocks and COVID-19 shares","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/5b0fd1107b67904376d520f7/1605181264572-cdacd921bc831520b170d39df57e1a89.jpeg?height=200","description":"<p>The UK Investor Magazine Podcast is joined by Alan Green for a run down of the dramatic moves in markets this week and exploration of scenarios going into the end of 2020.</p><p><br></p><p>The Biden Presidential victory has been overshadowed by news from Pfizer had a breakthrough in the fight against COVID-19 with a vaccine demonstrating 90% effectiveness. We look at the sharp rally in markets and question the sustainability going forward.</p><p><br></p><p>We discuss Novacyt (NCYT), Synairgen (SNG), Avacta (AVCT), Blue Prism (PRSM) and Capita (CPI).</p><p><br></p><p><br></p>","author_name":"UK Investor Magazine"}